Tina P T Koh
Overview
Explore the profile of Tina P T Koh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
208
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan A, Lai G, Saw S, Chua K, Takano A, Ong B, et al.
Cancer
. 2024 Feb;
130(10):1758-1765.
PMID: 38422026
Background: In early-stage non-small cell lung cancer (NSCLC), recurrence is frequently observed. Circulating tumor DNA (ctDNA) has emerged as a noninvasive tool to risk stratify patients for recurrence after curative...
2.
Tan A, Lai G, Tan G, Poon S, Doble B, Lim T, et al.
Lung Cancer
. 2019 Dec;
139:207-215.
PMID: 31835042
Objectives: There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker...
3.
Lai G, Lim T, Lim J, Liew P, Kwang X, Nahar R, et al.
J Clin Oncol
. 2019 Jan;
37(11):876-884.
PMID: 30676858
Purpose: Mesenchymal epithelial transition factor ( MET) activation has been implicated as an oncogenic driver in epidermal growth factor receptor ( EGFR)-mutant non-small-cell lung cancer (NSCLC) and can mediate primary...
4.
Nahar R, Zhai W, Zhang T, Takano A, Khng A, Lee Y, et al.
Nat Commun
. 2018 Jan;
9(1):216.
PMID: 29335443
EGFR-mutant lung adenocarcinomas (LUAD) display diverse clinical trajectories and are characterized by rapid but short-lived responses to EGFR tyrosine kinase inhibitors (TKIs). Through sequencing of 79 spatially distinct regions from...